Boundless Bio Q1 FY26 net loss narrows 14.01% to $13.6 million

• Boundless Bio posted a first-quarter net loss of USD 13.6 million, narrowing from USD 15.8 million a year earlier.
• R&D expense fell to USD 9.7 million from USD 12.1 million, while G&A expense eased to USD 4.7 million from USD 5.2 million.
• Cash, cash equivalents, and short-term investments totaled USD 92.8 million as of March 31, with runway expected into second-half 2028.
• Enrollment continued in KOMODO-1, a first-in-human trial of BBI-940 in ER+/HER2- breast cancer after CDK4/6 inhibitor and endocrine therapy, as well as TNBC-LAR; initial safety and efficacy proof-of-concept data are expected within existing cash runway.
• CEO Zachary Hornby cited new AACR poster data showing anti-tumor activity and tumor regression across multiple ecDNA+ cancer models supporting BBI-940’s kinesin degradation mechanism.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080700PRIMZONEFULLFEED9716173) on May 08, 2026, and is solely responsible for the information contained therein.